BCT BriaCell Therapeutics Corp

Note from BriaCell Management – October is Breast Cancer Awareness Month

Note from BriaCell Management – October is Breast Cancer Awareness Month
EN
01/10/2020

Underlying

BCTBriaCell Therapeutics Corp

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BriaCell Therapeutics Corp

 PRESS RELEASE
Free
BCT BriaCell Therap...

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive...

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License PHILADELPHIA and VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), are pleased to announce that they have entered into a definitive purchase agreement (the “Purchase Agreement”) pursuant to which BriaPro has agreed to purchas...

February 18, 2026 1 EN
 PRESS RELEASE
Free
BCT BriaCell Therap...

BriaCell Receives Positive Recommendation from Data Safety Monitoring ...

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitorFifth consecutive positive DSMB recommendation supports the favorable safety profile observed to datePhase 3 study is being conducted under FDA Fast Track Designation, reflecting the significant unmet need in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Feb. 17, 2026 (GLOBE NE...

February 17, 2026 1 EN
 PRESS RELEASE
Free
BCT BriaCell Therap...

BriaCell Patients’ Images Show Regression and Resolution of Metastasiz...

BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™ related discontinuations reported to dateBria-IMT regimen continues under Fast Track Designation from US FDA PHILADELPHIA and VANCOUVER, British Columbia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing nov...

January 28, 2026 1 EN
 PRESS RELEASE
Free
BCT BriaCell Therap...

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metasta...

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients 9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populationsNo Bria-IMT™ related discontinuations reported to dateBria-IMT regimen continues under Fast Track Designation from US FDA PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), ...

January 27, 2026 1 EN
 PRESS RELEASE
Free
BCT BriaCell Therap...

BriaCell Therapeutics Announces Closing of US$30 million Public Offeri...

BriaCell Therapeutics Announces Closing of US$30 million Public Offering PHILADELPHIA and VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts public offering of 5,366,726 units. Each unit consists of one common share (or one pre-funded warrant (“Pre-Funded Warrant”) in lieu thereof) and one warrant (the “Warrants”). Each...

January 15, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch